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ABSTRACT
The CEBPA gene is known to be mutated or abnormally expressed in several 
cancers. This is the first study assessing the clinical impact of CEBPA gene status and 
expression on the ovarian cancer outcome. The CEBPA gene sequence was analyzed 
in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 
74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood 
from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative 
PCR (qPCR)-based genotyping methods, respectively. The CEBPA mRNA level was 
examined with Reverse Transcription quantitative PCR (RT-qPCR). The results were 
correlated to different clinicopathological parameters. Thirty of 118 (25.4%) tumors 
harbored the CEBPA synonymous c.690G>T polymorphism (rs34529039), that we 
showed to be related to up-regulation of CEBPA mRNA levels (p=0.0059). The presence 
of the polymorphism was significantly associated with poor prognosis (p=0.005) 
and poor response to the PC chemotherapy regimen (p=0.024). In accordance, 
elevated CEBPA mRNA levels negatively affected patient survival (p<0.001) and 
tumor response to the PC therapy (p=0.014). The rs34529039 SNP did not affect the 
risk of developing ovarian cancer. This is the first study providing evidence that the 
c.690G>T, p.(Thr230Thr) (rs34529039) polymorphism of the CEBPA gene, together 
with up-regulation of its mRNA expression, are negative factors worsening ovarian 
cancer outcome. Their adverse clinical effect depends on a therapeutic regimen used, 
which might make them potential prognostic and predictive biomarkers for response 
to DNA-damaging chemotherapy.
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INTRODUCTION
Ovarian cancer is the most lethal gynecological 
malignancy and it remains the fifth most common cause 
of cancer-related death in women [1]. Surgical resection 
followed by the treatment with platinum compounds 
and taxanes is currently the standard therapy for patients 
with this disease. The majority of ovarian cancer 
patients develop resistance to chemotherapy and relapse. 
Consequently, the 5-years overall survival of patients with 
advanced ovarian carcinoma is merely 30% [2]. Efforts to 
improve patient survival include a search for genetic risk 
factors, prognostic biomarkers and biomarkers predictive 
of response to chemotherapy.
CCAAT enhancer-binding protein alpha (CEBPA) 
is a member of the bZIP family of transcription factors, 
encoded by an intronless gene localized in chromosome 
19q13.1 [3]. CEBPA is expressed in highly differentiated 
tissues; it promotes cell differentiation by transcriptional 
up-regulation of lineage-specific genes [4]. It also inhibits 
cell proliferation at the G1 phase of the cell cycle by 
interacting with other proteins [5, 6], such as: p21, CDK2, 
CDK4 and E2F, or by regulating the SWI/SNF chromatin-
remodeling complex. CEBPA takes part in the regulation 
of hematopoiesis [7, 8], and terminal differentiation of 
many cell types, including adipocytes, hepatocytes, and 
different epithelial cells [4, 9].
To date, there are no data in the literature showing 
how alterations in the CEBPA gene sequence and its 
expression may affect ovarian cancer prognosis and tumor 
response to chemotherapy. In our earlier pilot study, we 
identified this gene as a negative prognostic factor in 
ovarian cancer patients treated with DNA-damaging 
agents [8]. Here, we aimed to evaluate the prevalence of 
CEBPA gene mutations and polymorphisms in ovarian 
cancer patients, and also to look for associations between 
genetic alterations found and changes in the CEBPA 
mRNA expression levels.
RESULTS
Genotyping studies
We identified four types of known CEBPA 
polymorphisms: three synonymous single nucleotide 
polymorphisms (SNPs) and one duplication (Table 1). The 
most frequent alteration was: c.690G>T, p.(Thr230Thr), 
i.e., the SNP no. rs34529039, which was detected in 30 
of 118 (25.4%) ovarian cancer patients (both in tumors 
and blood samples). This polymorphism seemed not to 
influence the risk of developing ovarian cancer, since 
its frequency in healthy individuals 47/236 (19.9%) was 
similar to that observed in tumors (logistic regression 
model adjusted for age p=0.204). The second SNP 
(rs752254340), i.e., c.402G>A, p.(Ala134Ala) was 
present in four of 118 patients (3.4%), while the third SNP 
(rs192240793), i.e., c.573C>T, p.(His191His) – in one 
of 118 patients (0.8%). We did not assess the frequency 
of the last two SNPs in healthy individuals due to their 
rare occurrence in tumors, and the low probability of 
heterozygosity in the default global population, equaling 
0.1% and 3.3%, respectively [10]. Additionally, nine 
of 118 tumors (7.6%) had an in-frame duplication of 
six nucleotides c.584_589dupACCCGC, p.(His195_
Pro196dup) in the histidine and proline rich region 
(HPR) of the CEBPA TAD2 domain. This alteration was 
also present with a similar frequency (10/127; 7.9%) in 
healthy controls. No pathogenic CEBPA gene mutations 
were found.
The CEBPA gene alterations and clinical 
endpoints
We evaluated the clinical significance of the 
two most common CEBPA gene polymorphisms 
identified herein, c.690G>T, p.(Thr230Thr) and 
c.584_589dupACCCGC, p.(His195_Pro196dup), 
in ovarian cancer patients treated with platinum/
cyclophosphamide (PC) or taxane/platinum (TP) 
compounds. Clinical associations were found only for the 
c.690G>T, p.(Thr230Thr) SNP (Table 2). Multivariate 
statistical analyses revealed a positive association 
between the presence of this polymorphism and poor 
clinical outcome in all patients (the joined PC- and TP-
treated group) (HR 1.771, 95% CI 1.129-2.777, p=0.013). 
However, the analysis in the subgroups of patients treated 
with either the PC or TP revealed that the CEBPA c.690 
G>T SNP was associated with more than 3-fold increase of 
the risk of disease-related death in the PC-treated patients 
(HR 3.287, 95% CI 1.443-7.490, p=0.005). Noteworthy, 
such a correlation was not found in the TP-treated group, 
despite its larger size (Table 2, Figure 1A-1B).
In line with the prognostic results, the multivariate 
analysis of tumor response to chemotherapy revealed 
associations between the presence of the CEBPA c.690 
G>T SNP and almost 7-fold decrease of sensitivity to the 
PC treatment (OR 0.144, 95% CI 0.027-0.778, p=0.024) 
(Figure 1C). Accordingly, the chance for complete 
remission was over 5 times lower in patients harboring 
this polymorphism than in non-carriers, though this result 
was on the border of statistical significance (OR 0.188, 
95% CI 0.033-1.063, p=0.059) (Table 2).
Expression studies
CEBPA gene expression in ovarian cancer 
patients was evaluated at the RNA level with Reverse 
Transcription quantitative PCR (RT-qPCR). Noteworthy, 
although tumors from both the PC- and TP-treated patients 
were tested with this method, we obtained statistically 
significant results only for the former group. The 
multivariate Cox and logistic regression models showed 
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that CEBPA overexpression was a negative prognostic 
and predictive factor in these patients. This unfavorable 
clinical outcome was seen with all clinical measures 
assessed, including overall survival (OS), disease-free 
survival (DFS), and response to chemotherapy (Table 3, 
Figure 2A-2B).
We found that the presence of c.690G>T SNP 
(rs34529039) was related to the elevated expression of 
CEBPA mRNA (Mann-Whitney U test p=0.0059, Figure 
2C). This explains the concordance between the results 
of gene expression and genotyping studies in relation to 
patient outcome.
No significant correlation was found between 
levels of CEBPA mRNA expression or the presence of the 
CEBPA gene polymorphisms and the histological type of 
the tumor, tumor grade, tumor stage or patient age.
DISCUSSION
To date, the CEBPA c.690G>T SNP (rs34529039) 
was analyzed only in acute myeloid leukemia (AML) 
patients, where it occurred with a frequency ranging from 
3.6% to 32%, and was described as a non-pathogenic 
alteration [11, 12]. Its impact on cancer risk, prediction 
and prognosis has not yet been evaluated.
This is the first study to investigate the presence and 
significance of expression and gene status of CEBPA in 
ovarian cancer. For the first time, we suggest here that both 
the c.690G>T SNP and overexpression of CEBPA mRNA 
are negative prognostic and predictive factors in ovarian 
cancer patients treated with DNA-damaging agents (the 
PC regimen). We also showed that the presence of this 
SNP positively correlated with the elevated expression of 
CEBPA mRNA.
The c.690G>T SNP is a synonymous polymorphism 
in the Thr230 locus of the CEBPA protein which changes 
one threonine codon to another. Thus, the protein 
sequence remains the same. Nevertheless, some recent 
studies proved that synonymous codon substitutions may 
affect the kinetics of mRNA translation when frequency 
distribution of both codons in the genome significantly 
differs [13]. In compliance with these findings, in most of 
the human population, the CEBPA Thr230 is encoded by 
the ACG triplet, which occurs with the frequency equaling 
6.1 per 1000 codons (http://www.kazusa.or.jp/codon/). By 
contrast, the ACT codon, present in the c.690G>T SNP 
carriers, appears more than twice as often in the human 
genome (13.1 per 1000 codons). Furthermore, the latter 
codon is recognizable by more tRNA types than the 
dominant one due to a phenomenon known as the wobble 
base pairing. The difference in the prevalence of the 
aforementioned nucleotide triplets, and likely also the 
corresponding tRNA molecules [14], may change the rate 
of ribosome traffic, thus affecting the translation, folding, 
and subsequent modifications determining the CEBPA 
activity and function. The miRNA-based regulation of 
CEBPA expression may be impaired by such a codon 
alteration, too [15]. In accordance, some synonymous 
SNPs naturally occurring in the genome were shown to 
contribute to the development of various neoplasms, like 
AML, melanoma, and other types of cancer [15, 16].
Noteworthy, the Thr230 residue of CEBPA is 
known to be phosphorylated by the glycogen synthase 
kinase (GSK3). This mechanism plays a crucial role in the 
regulation of activity and intracellular levels of the CEBPA 
protein [17–19]. It is theoretically possible that the “silent” 
c.690G>T polymorphism at the Thr230 locus may hamper 
phosphorylation of CEBPA, leading to quantitative and 
Table 1: A detailed numerical characteristics of groups used in gene expression and genotyping studies along with 
the results of genotyping
Group
Type of 
expression 
analysis
Genotyped 
samples
c.690G>T 
carriers
c.584_589dupACCCGC 
carriers
c.402G>A 
carriers
c.573C>T 
carriers
PC-treated patients RT-qPCR 32 8 2 2 0
 none 12 3 0 0 0
       Partial sum 44 11 2 2 0
TP-treated patients RT-qPCR 74 19 7 2 1
       All patients 118 30 (1) 9 (0) 4 (1) 1 (0)
Healthy controls NA 236 47 (1)a 10 (0)b NAc NAc
        Total sum 354 77 (2) 19 (0) 4 (1) 1 (0)
NA – not applicable; Values in brackets represent the number of homozygotes for each polymorphism;
a The polymorphism was assessed in the entire group of 236 healthy women using the qPCR-based method;
b The polymorphism was assessed in a subgroup of 127 healthy women using the PCR and Sanger sequencing methods;
c The polymorphism was not assessed in healthy individuals.
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functional aberrations within the CEBPA protein and 
resultant impairment of its tumor suppressor role.
Herein, CEBPA overexpression was significantly 
correlated with poor prognosis and prediction of 
ovarian cancer patients, likely due to an oncogenic role 
that CEBPA apparently acquires in this neoplasm. The 
literature does not provide an explicit answer, whether 
CEBPA is an oncogene or a tumor suppressor. On one 
hand, inactivating mutations in the CEBPA gene have been 
described in about 10% - 15% of AML cases [20] (and 
rarely in non-hematologic malignancies [20, 21]), and they 
may result in loss of the protein function. In this disease, 
CEBPA activity may also be altered by the formation of 
AML1-ETO and AML1-MDS1-EVI1 fusion proteins, 
Table 2: The c.690G>T polymorphism of the CEBPA gene – statistical results of the multivariate analysis of 
prognosis (Cox proportional hazards model) and prediction (logistic regression model) in the PC-treated group, TP-
treated group, and the joined PC- and TP-treated groups of ovarian cancer patients
PC regimen
Analysis of prognosis Analysis of prediction
Variable name OS (41/44)
a
HR [95% CI] p
DFS (27/29)a
HR [95% CI] p
PS (22/44)a
OR [95% CI] p
CR (29/44)a
OR [95% CI] p
c.690G>T present vs absent 3.287 [1.443-7.490] 0.005 NS
0.144 [0.027-0.778] 
0.024
0.188 [0.033-1.063] 
0.059
Type (serous vs non-serous) 0.347 [0.138-0.873] 
0.025
-
35.37 [2.395-522.2] 
0.009
Rt ≤ 2cm vs 0cm
2.831 [1.157-6.928] 
0.023
- -
Rt > 2cm vs 0cm 2.311 [0.994-5.373] 
0.052
-
0.152 [0.025-0.904] 
0.038
TP regimen
Analysis of prognosis Analysis of prediction
OS (64/74)a
HR [95% CI] p
DFS (43/49)a
HR [95% CI] p
PS (43/74)a
OR [95% CI] p
CR (49/74)a
OR [95% CI] p
c.690G>T present vs absent NS NS NS NS
PC+TP regimens
Analysis of prognosis Analysis of prediction
OS (105/118)a
HR [95% CI] p
DFS (70/78)a
HR [95% CI] p
PS (65/118)a
OR [95% CI] p
CR (78/118)a
OR [95% CI] p
c.690G>T present vs absent 1.771 [1.129-2.777] 0.013 NS NS NS
Type (serous vs non-serous) 0.581 [0.350-0.963] 
0.035
FIGO IV vs (IIB+IIC) 1.924 [1.024-3.615] 
0.042
Rt ≤ 2cm vs 0cm
2.683 [1.551-4.641] 
<0.001
Rt > 2cm vs 0cm 3.300 [1.823-5.974] 
<0.001
a Values before and after a slash (/) in the analyses of prognosis stand for the number of completed observations vs all 
observations, respectively, whereas the same values in prediction tests represent the number of tumors positively responding 
to the treatment vs all tumors. Only the results with p-values < 0.1 are shown and those with p-values < 0.05 are highlighted in 
bold type. HR, OR, and CI stand for the hazard ratio, odds ratio, and confidence interval, respectively. OS – overall survival; 
DFS – disease-free survival; PS – platinum sensitivity; CR – complete remission; NS – a non-significant result (p ≥ 0.1).
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Figure 1: The c.690G>T SNP in the CEBPA gene as a negative prognostic and predictive factor. A-B. The presence of 
c.690G>T SNP increases the risk of death, but only in ovarian cancer patients treated with PC. Numbers of specimens below the Kaplan-
Meier plots refer to completed observations only. C. The same polymorphism significantly increases the resistance of tumors to DNA-
damaging agents.
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which down-regulates CEBPA expression at either the 
transcriptional or the translational level, respectively [22, 
23]. As for solid tumors, CEBPA protein expression was 
reported to be markedly diminished in lung, skin and 
breast cancers [24–26]. Down-regulation of CEBPA due 
to its promoter methylation was also reported in head and 
neck squamous cell carcinoma (HNSCC) [27].
On the other hand, CEBPA may also act as 
an oncogene in AML, since it was shown to inhibit 
both the intrinsic and extrinsic pathways of apoptosis 
by epigenetically activating the expression of two 
antiapoptotic genes, bcl2 and FLIP, respectively [28]. 
Chapiro et al. [29] reported that up-regulation of CEBPA 
may lead to the development of precursor B-cell acute 
lymphoblastic leukemia (BP-ALL). In this malignancy, 
CEBPA becomes overactive by juxtaposition to the 
immunoglobulin gene enhancer (the t(14;19)(q32;q13) 
chromosomal translocation), resulting in overexpression 
of CEBPA at both mRNA and protein levels.
Similarly, studies on human hepatocellular 
carcinomas (HCC) [30] showed up-regulation of CEBPA 
at both mRNA and protein levels. A forced down-
regulation of this gene led to reduced colony formation 
and cell growth. In line with these observations, Yin at 
al. have shown in their research on prostate cancer that 
up-regulation of CEBPA may cause the inactivation of the 
G1/S checkpoint, stimulation of a transition from the G1 
to S and G2 phases, stimulation of cell proliferation and 
enhancement of the anchorage-independent formation 
of colonies [31]. Inactivation of the G1/S checkpoint 
may protect cancer cells from apoptosis triggered off by 
DNA-damaging agents, causing a “replication by-pass”, 
Table 3: The CEBPA mRNA expression – statistical results of the multivariate analysis of prognosis (Cox 
proportional hazards model) and prediction (logistic regression model) in the PC-treated group, TP-treated group, 
and the joined PC- and TP-treated groups of ovarian cancer patients
PC regimen
Analysis of prognosis Analysis of prediction
Variable name OS (31/32)
a
HR [95% CI] p
DFS (20/22)a
HR [95% CI] p
PS (17/32)a
OR [95% CI] p
CR (22/32)a
OR [95% CI] p
CEBPA expression 
(high vs low)
171.7 [10.09-2923] 
<0.001
11728 [19.84->99999] 
0.004
7.85e-07 [1.12e-11-
0.055] 0.014
0.0002 [1.32e-07-
0.512] 0.033
Grade 4 vs (1+2) 3.413 [1.333-8.739] 
0.010
- - -
Rt > 2cm vs 0cm 2.908 [1.083-7.806] 
0.034
- - -
Rt ≤ 2cm vs 0cm
3.495 [1.206-10.13] 
0.021
- - -
TP regimen
Analysis of prognosis Analysis of prediction
OS (64/74)a
HR [95% CI] p
DFS (43/49)a
HR [95% CI] p
PS (43/74)a
OR [95% CI] p
CR (49/74)a
OR [95% CI] p
CEBPA expression 
(high vs low) NS NS NS NS
PC+TP regimens
Analysis of prognosis Analysis of prediction
OS (95/106)a
HR [95% CI] p
DFS (63/71)a
HR [95% CI] p
PS (60/106)a
OR [95% CI] p
CR (71/106)a
OR [95% CI] p
CEBPA expression 
(high vs low) NS NS NS NS
a Values before and after a slash (/) in the analyses of prognosis stand for the number of completed observations vs all 
observations, respectively, whereas the same values in prediction tests represent the number of tumors positively responding 
to the treatment vs all tumors. Only the results with p-values < 0.1 are shown and those with p-values < 0.05 are highlighted in 
bold type. HR, OR, and CI stand for the hazard ratio, odds ratio, and confidence interval, respectively. OS – overall survival; 
DFS – disease-free survival; PS – treatment sensitivity; CR – complete remission; NS – a non-significant result (p ≥ 0.1).
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Figure 2: Selected results of the statistical analysis of CEBPA mRNA expression. A. Evaluation of a prognostic value of 
altered CEBPA expression at the mRNA level in the PC-treated group. A dashed linear regression line is shown to visualize the trend of 
expression. B. Evaluation of a predictive value of altered CEBPA expression at the mRNA level in the PC-treated group. C. The analysis of 
a relationship between the presence of CEBPA c.690G>T SNP and elevated expression of CEBPA at the mRNA level. In all graphs, black 
lines on bars represent standard deviations of RT-qPCR measurements for each tumor.
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and potentially worsening the clinical outcome. In recent 
years, Zhao et al. [32] proved that overexpression of 
the CEBPA protein inhibits apoptosis elicited by DNA-
damaging agents in leukemic cells.
Our study corroborates these data, since all clinical 
associations of CEBPA overexpression and/or the 
presence of the c.690G>T SNP we found, were confined 
to the patients treated solely with DNA-damaging agents. 
None of these associations were observed in the TP-
treated patients, who were administered mainly with 
taxol, a compound with a different mechanism of action, 
despite the larger size of the latter group. Consistently, 
the statistical results (related to overall survival only), 
that we obtained on combining the PC- and TP-treated 
groups, were also significant, although at a lower level of 
significance. This supported our preliminary assumption 
that such analyses ought to be conducted in uniformly 
treated groups of patients.
Our study throws some light on the mechanisms by 
which taxanes overcome resistance observed for regimens 
based on DNA-damaging agents only. Apparently, 
the CEBPA overexpression and/or the presence of the 
c.690G>T SNP does not interfere with actions of taxanes, 
which are known to stabilize microtubules, causing the 
cell cycle arrest in the G2/M phase [33].
DNA-damaging agents only may be used as 
second- and further lines of chemotherapy for ovarian 
cancer patients. The clinical associations that we report 
herein are conceivably potentially applicable to other 
malignancies treated with DNA damaging agents, such as 
lung cancers, testicular cancers, melanomas, myelomas 
and lymphomas [34].
Finally, Yoon and Smart [35] identified nine 
potential TP53 binding sites in the CEBPA promoter, and 
demonstrated that CEBPA is a DNA damage-inducible 
TP53-regulated mediator of the G1/S checkpoint in 
keratinocytes. Thus, abnormalities within TP53 (which are 
common in ovarian cancer [36]) may disturb the normal 
physiological function of CEBPA and change the way it 
affects ovarian cancer development and prognosis. As a 
confirmation of this hypothesis, Seipel et al. [37] have 
recently shown that restoring the TP53 function after 
treatment with cytotoxic chemotherapy compounds and 
TP53 restoring non-genotoxic agents induced CEBPA 
gene expression, myeloid differentiation, and cell-cycle 
arrest in AML cells. Furthermore, the development of 
ovarian cancer is considered to potentially depend on 
the levels of androgens and gonadotropins [38, 39]. 
Fan et al. [40] proved that the CEBPA and CEBPB 
proteins are essential for some gonadotropins-dependent 
processes, such as ovulation, luteinization and terminal 
differentiation of granulosa cells. Thus, involvement of 
CEBPA in ovarian carcinogenesis through the pathways 
associated with hormones cannot be excluded, either.
In summary, we show here for the first time that the 
c.690G>T SNP (rs34529039) in the CEBPA gene, along 
with CEBPA overexpression at the mRNA level, constitute 
factors of poor prediction and prognosis in ovarian 
cancer patients treated with DNA-damaging agents. 
These findings may have implications for the choice of 
chemotherapy in ovarian cancer patients, and also in 
patients with other cancers treated with DNA-damaging 
agents.
MATERIALS AND METHODS
Patients and tumors
The studied material comprised ovarian carcinoma 
tumor samples and blood samples from 118 patients 
(age range: 20-76 years, median age: 53 years). Samples 
were collected in the Institute of Oncology, and in the 
Brodnowski Hospital, Warsaw, Poland in the period 
between 1995-2010. Medical records were critically 
reviewed and relevant data extracted by at least two 
clinicians for patient selection according to the following 
selection criteria: no chemotherapy before staging 
laparotomy, adequate staging procedure, International 
Federation of Gynecologists and Obstetricians (FIGO) 
stage IIB to IV disease [41], tumor tissue from the 
first laparotomy available, moderate or poor tumor 
differentiation, availability of clinical information, 
including the residual tumor size and follow-up data. 
All tumors were uniformly reviewed histopathologically, 
classified according to the World Health Organization 
[42], and graded in a four-grade scale, in compliance with 
the standards given by Barber et al. [43].
The clinical material comprised tumor samples from 
44 patients treated with cisplatin and cyclophosphamide 
(the PC regimen; age range: 34-76 years, median age: 55.5 
years), and 74 patients treated with cisplatin or carboplatin 
and taxanes (the TP regimen; age range: 20-74 years, 
median age: 53 years). We managed to extract RNA of 
sufficient quality for a Reverse Transcription quantitative 
PCR (RT-qPCR) analysis of CEBPA expression from 106 
of 118 tumors. Detailed clinicopathological characteristics 
of the patients are shown in Table 4, while Table 1 presents 
numerical characteristics of the analyzed groups.
Response to chemotherapy was evaluated on 
the basis of patient condition and CA125 3-4 week 
post chemotherapy. As to the assessment of clinical 
endpoints, complete remission (CR) was defined as 
disappearance of all clinical and biochemical symptoms 
of ovarian cancer evaluated after completion of the first-
line chemotherapy and confirmed four weeks later [44]. 
Tumors were considered sensitive to the treatment when 
disease-free survival of patients was longer than or equal 
to six months. Otherwise, tumors were presumed to be 
resistant [45]. Disease-free survival (DFS) time was 
assessed only for the patients who achieved complete 
remission. For the PC-treated group, the follow-up time 
ranged from 104 to 3750 days (median: 915.5 days); 
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Table 4: A clinicopathological characteristics of patients
PC regimen (N=44) TP regimen (N=74) PC+TP regiment (N=118)
Age (years)
Range (median) 34-76 (55.5) 20-74 (53) 20-76 (53)
Histological type
Serous 38 (86.4%) 58 (78.4%) 96 (81.4%)
Endometrioid 2 (4.6%) 2 (2.7%) 4 (3.4%)
Undifferentiated 1 (2.3%) 7 (9.5%) 8 (6.8%)
Other types 3 (6.8%) 7 (9.5%) 10 (8.5%)
Histological grade
G2 4 (9.1%) 8(10.8%) 12 (10.2%)
G3 25 (56.8%) 44 (59.5%) 69 (58.5%)
G4 15 (34.1%) 22 (29.7%) 37 (31.4%)
Clinical stage (FIGO)
IIB, IIC 2 (4.6%) 2 (2.7%) 4 (3.4%)
IIIA, IIIB 7 (15.9%) 8 (10.8%) 15 (12.7%)
IIIC 30 (68.2%) 57 (77.0%) 87 (73.7%)
IV 5 (11.4%) 7 (9.5%) 12 (10.2%)
Residual tumor size
0 cm 10 (22.73%) 15 (20.3%) 25 (21.2%)
≤ 2 cm 14 (31.8%) 42 (56.8%) 56 (47.5%)
> 2 cm 20 (45.5%) 17 (23.0%) 37 (31.4%)
Overall survival (days)
Range (median) 104-3750 (915.5) 296-5630 (1010) 104-5630 (1007)
Disease-free survival (days)
Range (median) 95-2521 (393) 96-2884 (414) 95-2884 (413)
Outcome
NED 1 (2.3%) 8 (10.8%) 9 (7.6%)
AWD 2 (4.6%) 2 (2.7%) 4 (3.4%)
DOD 41 (93.2%) 64 (86.5%) 105 (89.0%)
Sensitivity to treatment
Sensitive 22 (50%) 43 (58.1%) 65 (55.1%)
Resistant 22 (50%) 31 (41.9%) 53 (44.9%)
Response to therapy
Complete remission 29 (65.9%) 49 (66.2%) 78 (66.1%)
Othera 15 (34.1%) 25 (33.8%) 40 (33.9%)
NED – no evidence of disease; AWD – alive with disease; DOD – died of disease; NA – not applicable.
a) Other responses include: partial remission, progression, and no change.
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the respective values for the TP-treated group equaled 
296 and 5630 days (median: 1010 days). All surviving 
patients had at least a 2-year follow-up duration. Shorter 
follow-up times were due to earlier patient death. 
Completed observations were defined as those where 
the follow-up ended with patient death (OS) or relapse 
of a tumor (DFS).
Initially, the control group comprised blood samples 
from 127 healthy women (age range: 19-75 years, median 
age: 52 years). Just like ovarian tumors, they were assessed 
for the presence of polymorphisms and mutations within 
the CEBPA gene using the PCR and Sanger sequencing 
methods. Later, in order to unequivocally decide the 
question whether the c.690G>T, p.(Thr230Thr) SNP 
(rs34529039) impacts on the risk of developing ovarian 
cancer, the control group was extended to 236 healthy 
women (age range: 19-75 years, median age: 50 years), 
and genotyped with Real-Time quantitative PCR (qPCR) 
(see Table 1).
This study was approved by the Bioethics 
Committee of Maria Sklodowska-Curie Memorial 
Cancer Center and Institute of Oncology (ref. no. 
39/2007).
DNA and RNA extraction
Tumors obtained during the surgical procedure as 
well as the relevant blood samples anticoagulated with 
EDTA were snap-frozen in liquid nitrogen and stored 
at -70°C. Blood samples from the control group were 
collected and stored likewise. Tumor cryostat sections 
were stained with hematoxylin and eosin, and then 
evaluated by a pathologist (JK) to determine the amount 
of tumor content and viability. The viable epithelial 
tumor cell content had to be at least 85%. Genomic 
DNA was extracted with the use the QIAmp DNA 
Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. RNA was isolated using the 
RNeasy Plus Mini Kit (Qiagen), equipped with gDNA 
Eliminator columns. RNA quantity was measured with 
NanoDrop spectrophotometer (Thermo-Fisher Scientific, 
Waltham, MA, USA), and its quality assessed on Agilent 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). RNA integrity numbers (RINs) of the samples 
ranged from 6.5 to 9.4.
Molecular analysis of the CEBPA gene
Polymerase chain reaction (PCR)-based DNA 
amplification followed by Sanger sequencing was 
carried out to identify mutations and polymorphisms 
within the CEBPA gene. The entire coding region of 
the gene was amplified by PCR in two steps utilizing 
three pairs of primers, designed with the NCBI Primer-
BLAST software, and the CEBPA genomic sequence 
(GenBank Accession No: NG_012022.1). In the first 
round of PCR, the entire coding sequence (1388 bp) 
was amplified using two outer primers: (forward, OF) 
5’-ATGCCGGGAGAACTCTAACT -3’ and (reverse, 
OR) 5’-ACCGGAATCTCCTAGTCCTG- 3’. In 
the second round, two nested PCRs were run using 
the product of the first PCR reaction as a template, 
and two pairs of inner primers: (forward, IF1) 
5’-ATGCCGGGAGAACTCTAACT-3’, (reverse, IR1) 
5’-CAGGTGCATGGTGGTCTG-3’, and (forward, 
IF2) 5’-GGCCTCTTCCCTTACCAG-3’, (reverse, IR2) 
5’-ACCGGAATCTCCTAGTCCTG-3’. The products 
of the nested PCR were 685 bp and 668 bp long, 
respectively). PCR mixtures were prepared according 
to the standard procedure (Applied Biosystems, 
Waltham, MA, USA) with addition of 5 mM betaine 
(Sigma-Aldrich, St. Louis, MO, USA). PCR reactions 
were performed in the Gene Amp 9700 thermal cycler 
(Applied Biosystems) with an initial denaturation step 
at 94°C for 10 min, followed by 36 cycles consisting 
of: denaturation (94°C, 90 s), annealing (55°C, 45 s), 
extension (72°C, 90 s) in the first PCR, and denaturation 
(94°C for 30 s), annealing (55°C, 20 s), extension (72°C, 
50 s) in nested PCRs. The final extension step (10 min, 
72°C) was the same in all PCRs.
PCR products were purified enzymatically 
with exonuclease I and alkaline phosphatase 
(illustra ExoProStar, GE Healthcare Life Sciences, 
Little Chalfont, UK), and then sequenced in both 
directions using the BigDye Terminator v3.1 Cycle 
Sequencing Kit (Life Technologies, Carlsbad, CA, 
USA) on an automated ABI PRISM 3100 Sequencer 
(Life Technologies) according to the manufacturer’s 
recommendations.
Additionally, the c.690G>T, p.(Thr230Thr), 
(rs34529039) SNP was assessed by qPCR-based 
genotyping in the extended group of 236 healthy 
women. This study was carried out on the 7500 Fast 
Real-Time PCR System (Life Technologies) using two 
different Custom TaqMan Genotyping Assays (ID: 
AHCTFCJ, lot numbers: 1500898_B1 and 1505907_
A10, Life Technologies), tested by the manufacturer. 
Only those genotyping calls which were fully consistent 
for both assays were taken into account. The qPCR 
reactions were performed in the volume of 11 μl using 
the SensiFAST™ Lo-ROX Genotyping Kit (Bioline, 
London, UK) and about 25 ng of genomic DNA per well. 
The thermal profile of qPCR (the same for both TaqMan 
assays) was as follows: 60°C for 1 min. (pre-PCR read), 
95°C for 3 min. (hot start of the polymerase) followed 
by 40 cycles with all the standard ramp speeds decreased 
by 50%, consisting of three steps: denaturation (95°C, 30 
s), annealing (59°C, 30 s), and extension (60°C, 1 min.), 
and then the final post-PCR read (60°C, 1 min.). In each 
qPCR reaction the ROX dye was used as a passive 
reference.
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Reverse Transcription quantitative PCR 
(RT-qPCR)-based studies of CEBPA mRNA 
expression
All RT-qPCRs were performed on the 7500 Fast 
Real-Time PCR System (Life Technologies), using 
HGPRT as a reference gene. Gene expression was 
evaluated with TaqMan assays, CEBPA-specific (6-FAM-
labeled, Life Technologies, assay id: Hs00269972_s1) 
and HGPRT-specific (VIC-labeled, Life Technologies, 
assay id: 4326321E). RT-qPCRs were run in triplicates 
as multiplex reactions in the volume of 11 μl using 
TaqMan Universal PCR Master Mix with uracil 
N-glycosylase (Life Technologies) and about 10-11 ng 
of total RNA, earlier reverse transcribed to cDNA with 
the Superscript III First-Strand Synthesis System (Life 
Technologies). Obtained expression data were quantified 
using a standard curve prepared from one of the analyzed 
samples. Efficiency of RT-qPCR reactions ranged from 
80% to 110%, as assessed based on slopes of the standard 
curves. The coefficient of determination (R2) of the curves 
was always higher than 0.99 [46].
The reference gene used in this study, HGPRT, was 
nominated from among 11 genes included on TaqMan 
Human Endogenous Control Plates (Life Technologies), 
because it was characterized by the most stable expression 
in both the PC- and TP-treated groups of patients. 
Expression of the reference genes was assessed for 8 
randomly selected tumors from each group. Then, the 
stability of expression was calculated with the qBasePLUS 
software (Biogazelle NV, Zwijnaarde, Belgium) [47].
Statistical analyses
The statistical significance of changes in CEBPA 
mRNA expression and sequence alterations within this 
gene was assessed using the multivariate Cox proportional 
hazards model (prognostic value) or multivariate logistic 
regression model (predictive value). Changes in gene 
status and levels of expression of CEBPA were correlated 
with clinicopathological tumor characteristics, including: 
patient age (categorized by median split); residual tumor 
size; clinical stage (FIGO); histological grade (the last 
three parameters were categorized as shown in Table 
4), and histological type (categorization: serous vs non-
serous types). Additionally, the multivariate logistic 
regression model adjusted for age enabled us to evaluate 
whether there was a difference in frequency distribution of 
identified CEBPA gene alterations between ovarian cancer 
patients and healthy women. All multivariate statistical 
models were simplified by backward stepwise elimination 
of variables if their individual p-values were higher than 
or equal to 0.1.
Afterwards, we used the Mann-Whitney U or 
Kruskal-Wallis test to determine direct associations of 
CEBPA mRNA expression (continuous data) with each 
variable included in multivariate analyses, and also with 
polymorphisms identified herein. In case of categorical 
data, i.e., the CEBPA genotyping results (binomial 
categorization), the same relationships were looked for, 
but with the use of chi-square or Fisher's exact probability 
tests, depending on the size of the analyzed groups. In all 
the tests the statistical significance level (alpha) was set 
to 0.05.
Noteworthy, in this study, CEBPA mRNA expression 
was always treated as a continuous variable to avoid 
arbitrary categorization of data, which could potentially 
lead to falsification of statistical results. A tumor exhibiting 
the highest expression of the CEBPA transcript was used 
as a calibrator. Thus, all the expression values ranged from 
0 to 1. This approach allowed for approximate estimation 
of the risks based on the hazards ratios (HRs) and odds 
ratios (ORs) in a similar way as for categorical variables. 
However, given that only one tumor (calibrator) had the 
CEBPA mRNA expression equaling 1, and none – equaling 
0, the real increase or decrease of the risk was always 
lower than that estimated on the basis of HRs and ORs 
shown in Table 3.
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